Sonnet BioTherapeutics (SONN) shares were up 3% Friday after the company said that safety results from a phase 1b/2a trial of SON-1010 plus atezolizumab in patients with advanced solid tumors or platinum-resistant ovarian cancer were "positive."
The study aimed to test the safety, tolerability, and effectiveness of increasing doses of SON-1010 with atezolizumab. The main goal was to find the maximum tolerated dose when combined with the immune checkpoint inhibitor. A total of 19 patients were treated, and one patient with platinum-resistant ovarian cancer showed a partial response at the highest dose, the company said.
Based on positive feedback from the Safety Review Committee, the biotechnology company also said that the study will move to an expansion phase, which will assess the preliminary effects of the combination at the highest dose, leading to a phase 2a comparison with the standard treatment.
Price: 1.31, Change: +0.04, Percent Change: +3.07
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.